NT 201: Clinical Trials

15 trials of NT 201, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 5 active not recruiting. 15 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 315Completed 10, Active not recruiting 5

Follow NT 201: new trials by email Literature Review of NT 201 trials Research Report on NT 201

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
NT 201, NT 201 Placebo - Neuromuscular Agents, Peripheral Nervous System Agents
Phase 3Active not recruitingMerz Aesthetics GmbH3002025-10-012026-11-06
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NT 201, NT 201 Placebo - Neuromuscular Agents, Peripheral Nervous System Agents
Phase 3Active not recruitingMerz North America, Inc.3002025-08-272026-09-10
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Xeomin, Placebo - Chronic Migraine
Phase 3Active not recruitingMerz Therapeutics GmbH8082025-08-212026-10-14
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Xeomin, Placebo - Episodic Migraine
Phase 3Active not recruitingMerz Therapeutics GmbH9972025-08-212026-10-14
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
NT 201, Placebo - Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Phase 3CompletedMerz North America, Inc.3682020-11-122024-08-06
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
NT 201, Placebo - Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Phase 3CompletedMerz North America, Inc.3622020-09-232024-05-08
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NT 201, Placebo - Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Phase 3Active not recruitingMerz Pharmaceuticals GmbH6032019-09-162026-10-20
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NT 201 Placebo, NT 201 - Chronic Troublesome Sialorrhea, Cerebral Palsy
Phase 3CompletedMerz Pharmaceuticals GmbH2562015-02-092021-08-10
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units), Placebo - Chronic Troublesome Sialorrhea, Parkinson's Disease
Phase 3CompletedMerz Pharmaceuticals GmbH1842014-04-012018-03-27
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight) - Cerebral Palsy, Spasticity
Phase 3CompletedMerz Pharmaceuticals GmbH3512014-03-282021-08-05
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
IncobulinumtoxinA (Xeomin), 25 Units, IncobotulinumtoxinA (Xeomin), 12.5 Units, Placebo - Bilateral Blepharospasm (BEB)
Phase 3CompletedMerz Pharmaceuticals GmbH612013-11-012018-03-01
Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
IncobotulinumtoxinA (16-20 Units per kg body weight) - Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy
Phase 3CompletedMerz Pharmaceuticals GmbH3702013-08-012017-10-27
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
IncobotulinumtoxinA (16 Units per kg body weight), IncobotulinumtoxinA (12 Units per kg body weight), IncobotulinumtoxinA (4 Units per kg body weight) - Lower Limb Spasticity Due to Cerebral Palsy
Phase 3CompletedMerz Pharmaceuticals GmbH3112013-06-012021-08-05
Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
NT 201 - Healthy
Phase 3CompletedMerz Pharmaceuticals GmbH1082008-05-012012-10-30
IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity
incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kD), free from complexing proteins") - Upper Limb Spasticity
Phase 3CompletedMerz Pharmaceuticals GmbH2162007-02-012010-12-31

Conditions studied

Brain Injuries, Traumatic (3)  ·  Cerebral Palsy (2)  ·  Intellectual Disability (1)  ·  Muscle Spasticity (1)  ·  Parkinson Disease (1)  ·  Stroke (1)

Sponsors

Merz Pharmaceuticals GmbH (9)  ·  Merz North America, Inc. (3)  ·  Merz Therapeutics GmbH (2)  ·  Merz Aesthetics GmbH (1)

Countries

Germany (10)  ·  Poland (9)  ·  France (6)  ·  Spain (6)  ·  United States (6)  ·  Austria (5)  ·  Czechia (5)  ·  Russia (5)  ·  Slovakia (5)  ·  Ukraine (5)  ·  Italy (4)  ·  Switzerland (4)  ·  United Kingdom (4)  ·  Canada (3)  ·  Denmark (2)

Top investigators

Matthias Imhof, MD (1)  ·  Michael P Barnes, MD, FRCP (1)

Results publications

PMID 36136523, PMID 39475143, PMID 40968493, PMID 22010053, PMID 30918101, PMID 31794936, PMID 32779096, PMID 33211907, PMID 34092664, PMID 34339951, PMID 34341153, PMID 34384301, PMID 34957963

NIH funding

2008 (1), 2018 (1), 2019 (1)